Revelation Biosciences, Inc.
REVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001810560
No open-market purchases or sales by Revelation Biosciences, Inc. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $313.2K in total; no superinvestor holds it.
Other share classesREVBW
13F holders, Q1 2022
Institutional positions in Revelation Biosciences, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- +14 vs. Q4 2021
- Shares held
- 3.02M
- +2.95M (+4,593.4%) vs. Q4 2021
- Total value
- $3.44M
- +$2.78M (+423.2%) vs. Q4 2021
- New holders
- 16
- 0 more added
- Sold out
- 2
- 0 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting REVB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 12 | $313.2K |
| Q1 2026 | 12 | $599.8K |
| Q4 2025 | 14 | $984.3K |
| Q3 2025 | 10 | $539.7K |
| Q2 2025 | 8 | $64.2K |
| Q1 2025 | 7 | $13.3K |
| Q4 2024 | 10 | $49.4K |
| Q3 2024 | 7 | $84.3K |
| Q2 2024 | 7 | $95.8K |
| Q1 2024 | 7 | $20.9K |
| Q4 2023 | 10 | $467.3K |
| Q3 2023 | 11 | $656.3K |
| Q2 2023 | 10 | $758.7K |
| Q1 2023 | 11 | $1.05M |
| Q4 2022 | 10 | $426.9K |
| Q3 2022 | 14 | $588.6K |
| Q2 2022 | 12 | $3.57M |
| Q1 2022 | 16 | $3.44M |
| Q4 2021 | 2 | $657.0K |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Revelation Biosciences, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AXA S.A. | 1,958,984 | $2.23M | 0.01% | +1,958,984 | New |
| Monashee Investment Management LLC | 817,562 | $932.0K | 0.27% | +817,562 | New |
| Citadel Advisors LLC | 42,633 | $49.0K | 0.00% | +42,633 | New |
| Bridgeway Capital Management, LLC | 39,800 | $45.0K | 0.00% | +39,800 | New |
| Two Sigma Investments, LP | 32,540 | $37.0K | 0.00% | +32,540 | New |
| HRT Financial LP | 23,751 | $27.0K | 0.00% | +23,751 | New |
| Ergoteles LLC | 22,327 | $25.0K | 0.00% | +22,327 | New |
| Mayflower Financial Advisors, LLC | 21,425 | $24.0K | 0.00% | +21,425 | New |
| Jane Street Group, LLC | 19,536 | $22.0K | 0.00% | +19,536 | New |
| Virtu Financial LLC | 14,906 | $17.0K | 0.00% | +14,906 | New |
| Valeo Financial Advisors, LLC | 10,000 | $11.0K | 0.00% | +10,000 | New |
| Morgan Stanley | 4,289 | $5.00K | 0.00% | +4,289 | New |
| Tower Research Capital LLC (TRC) | 3,502 | $4.00K | 0.00% | +3,502 | New |
| UBS Group AG | 3,736 | $4.00K | 0.00% | +3,736 | New |
| Citigroup Inc | 1,830 | $2.00K | 0.00% | +1,830 | New |
| Wells Fargo & Company | 32 | $0 | 0.00% | +32 | New |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −49,678−100.0% | Sold out |
| Yakira Capital Management, Inc. | 0 | $0 | 0.00% | −14,600−100.0% | Sold out |